ClinicalTrials.gg
CompletedNCT03001076Updated May 11, 2020Results posted

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

A Phase 3 interventional study of Bempedoic acid and Ezetimibe in Hypercholesterolemia, Atherosclerosis and Statin Adverse Reaction, sponsored by Esperion Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-11.

Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
269
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
7th of 21
269 · median 126
Started
2016
with 3 others
Phase 3
7 of 21
1 open now
Registered
10th of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 7th largest by enrollment, is one of 4 that started in 2016, is one of 7 in phase 3, and was the 10th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.

03

Conditions studied

  • Hypercholesterolemia
  • Atherosclerosis
  • Statin Adverse Reaction

Keywords

  • hyperlididemia
  • LDL
  • cholesterol
  • statin intolerance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting LDL-cholesterol greater than or equal to 100 mg/dL at screening
  • Men and nonpregnant, nonlactating women
  • Use of stable lipid-modifying therapy for at least 4 weeks prior to screening that includes ezetimibe 10mg daily

Exclusion criteria

Exclusion Criteria:

  • Fasting blood triglycerides greater than or equal to 500 mg/dL
  • (BMI) greater than or equal to 50 kg/m2
  • Recent history of cardiovascular disease
  • Use of statin therapy where doses are greater than those defined as "low-dose" within 4 weeks prior to screening; where "low-dose" is defined as an average daily dose of rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg, or pitavastatin 2 mg.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    bempedoic acid

    bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)

    Drug: Bempedoic acid · Drug: Ezetimibe

  • Placebo comparator
    placebo

    Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)

    Drug: Ezetimibe · Other: Placebo

Interventions

  • bempedoic acid 180 mg tablet

    Also known as: ETC-1002

  • ezetimibe 10 mg tablet

    Also known as: Zetia

  • OtherPlacebo

    matching placebo tablet

    Also known as: placebo control

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[LDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Bempedoic Acid = BA. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

    Time frame: Week 12

Secondary outcomes

  1. Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for non-HDL-C. Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[non-HDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing non-HDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

    Time frame: Week 12

  2. Percent Change From Baseline to Week 12 in Total Cholesterol (TC)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for TC. Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[TC value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing TC data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

    Time frame: Week 12

  3. Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for apoB. Baseline was defined as the last non-missing value on or prior to Day 1. Percent change from baseline was calculated as: \[(apoB value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in apoB was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing apoB data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

    Time frame: Week 12

  4. Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for hsCRP. Baseline was defined as the last non-missing value on or prior to Day 1. Percent change from baseline was calculated as: \[(hsCRP value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100.

    Time frame: Week 12

  5. Percent Change From Baseline to Week 12 in Triglycerides (TGs)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TGs. Baseline was defined as the mean of the TGs values from the last two non-missing values on or prior to D 1. Percent change from baseline was calculated as: \[(TGs value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TGs was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

    Time frame: Week 12

  6. Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for HDL-C. Baseline was defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(HDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

    Time frame: Week 12

  7. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs, defined as an adverse events (AEs) that began or worsened in severity after the first dose of double-blind study drug and prior to the last dose of double-blind study drug + 30 days, were collected and reported.

    Time frame: Up to approximately 16 weeks

Other outcomes

  1. Percent Change From Baseline to Weeks 4 and 8 in LDL-C

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(LDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

    Time frame: Week 4 and Week 8

  2. Percent Change From Baseline to Weeks 4 and 8 in Non-HDL-C

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for Non-HDL-C. Baseline was defined as the mean of the Non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(Non-HDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

    Time frame: Week 4 and Week 8

  3. Percent Change From Baseline to Weeks 4 and 8 in TC

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(TC value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

    Time frame: Week 4 and Week 8

  4. Percent Change From Baseline to Weeks 4 and 8 in TGs

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for TGs. Baseline was defined as the mean of the TGs values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(TGs value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TGs was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

    Time frame: Week 4 and Week 8

  5. Percent Change From Baseline to Weeks 4 and 8 in HDL-C

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for HDL-C. Baseline was defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(HDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

    Time frame: Week 4 and Week 8

  6. Absolute Change From Baseline to Weeks 4, 8, and 12 in LDL-C

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Absolute change from baseline was calculated as: LDL-C value at Week 4, 8, or 12 minus Baseline value.

    Time frame: Week 4, Week 8 and Week 12

07

Results

Posted Apr 3, 2020

Participant flow

Out of the 269 participants who were randomized to the double-blind treatment period, 181 participants were randomized to bempedoic acid and 88 participants to placebo. One participant in the placebo group was randomized but never started treatment.

Participant flow — Overall Study
MilestonePlaceboBempedoic Acid
Started88181
Completed81176
Not completed75
Withdrew: Withdrawal by patient20
Withdrew: Other10
Withdrew: Adverse event33
Withdrew: Sponsor decision10
Withdrew: Lost to follow-up02

Outcome measures

PrimaryPercent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[LDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Bempedoic Acid = BA. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

Time frame:
Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C)4.99 ± 2.299-23.46 ± 1.945
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -28.45 · 95% CI -34.376 to -22.531
SecondaryPercent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for non-HDL-C. Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[non-HDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing non-HDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

Time frame:
Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)5.19 ± 2.202-18.38 ± 1.668
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -23.56 · 95% CI -29.005 to -18.121
SecondaryPercent Change From Baseline to Week 12 in Total Cholesterol (TC)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for TC. Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[TC value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing TC data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

Time frame:
Week 12
Reported as:
Least squares mean · Percent change
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
Percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)2.88 ± 1.553-15.11 ± 1.282
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -17.99 · 95% CI -21.940 to -14.030
SecondaryPercent Change From Baseline to Week 12 in Apolipoprotein B (apoB)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for apoB. Baseline was defined as the last non-missing value on or prior to Day 1. Percent change from baseline was calculated as: \[(apoB value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in apoB was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing apoB data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

Time frame:
Week 12
Reported as:
Least squares mean · Percent change
Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB)
Percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB)4.74 ± 1.786-14.58 ± 1.497
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -19.32 · 95% CI -23.908 to -14.732
SecondaryPercent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for hsCRP. Baseline was defined as the last non-missing value on or prior to Day 1. Percent change from baseline was calculated as: \[(hsCRP value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100.

Time frame:
Week 12
Reported as:
Median · Percent change
Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)
Percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)2.088 (-32.143 to 49.224)-32.521 (-55.556 to 10.714)
Statistical analysis
  • Placebo vs Bempedoic Acid · Wilcoxon Rank Sum Test · p = <0.001 · Location shift: -31.045 · 95% CI -44.761 to -17.401The location shift and asymptotic 95% confidence interval are based on Hodges-Lehman estimation.
SecondaryPercent Change From Baseline to Week 12 in Triglycerides (TGs)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TGs. Baseline was defined as the mean of the TGs values from the last two non-missing values on or prior to D 1. Percent change from baseline was calculated as: \[(TGs value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TGs was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

Time frame:
Week 12
Reported as:
Least squares mean · Percent change
Percent Change From Baseline to Week 12 in Triglycerides (TGs)
Percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Triglycerides (TGs)9.23 ± 4.2184.70 ± 3.068
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = =0.388 · Difference in ls mean: -4.53 · 95% CI -14.877 to 5.812
SecondaryPercent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for HDL-C. Baseline was defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(HDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

Time frame:
Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)-1.38 ± 1.389-7.27 ± 1.214
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = =0.002 · Difference in ls mean: -5.89 · 95% CI -9.528 to -2.250
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs, defined as an adverse events (AEs) that began or worsened in severity after the first dose of double-blind study drug and prior to the last dose of double-blind study drug + 30 days, were collected and reported.

Time frame:
Up to approximately 16 weeks
Reported as:
Number · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlaceboBempedoic Acid
TEAEs3988
Non-serious TEAEs1846
Serious TEAEs35
Deaths00
Other pre-specifiedPercent Change From Baseline to Weeks 4 and 8 in LDL-C

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(LDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

Time frame:
Week 4 and Week 8
Reported as:
Least squares mean · Percent change
Percent Change From Baseline to Weeks 4 and 8 in LDL-C
Percent changePlaceboBempedoic Acid
Week 43.05 ± 1.442-28.04 ± 1.704
Week 83.61 ± 1.773-25.51 ± 1.773
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -31.09 · 95% CI -35.498 to -26.682
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -29.12 · 95% CI -34.074 to -24.168
Other pre-specifiedPercent Change From Baseline to Weeks 4 and 8 in Non-HDL-C

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for Non-HDL-C. Baseline was defined as the mean of the Non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(Non-HDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

Time frame:
Week 4 and Week 8
Reported as:
Least squares mean · Percent change
Percent Change From Baseline to Weeks 4 and 8 in Non-HDL-C
Percent changePlaceboBempedoic Acid
Week 43.08 ± 1.362-22.17 ± 1.457
Week 83.71 ± 1.660-20.04 ± 1.531
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -25.26 · 95% CI -29.204 to -21.308
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -23.75 · 95% CI -28.219 to -19.276
Other pre-specifiedPercent Change From Baseline to Weeks 4 and 8 in TC

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(TC value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

Time frame:
Week 4 and Week 8
Reported as:
Least squares mean · Percent change
Percent Change From Baseline to Weeks 4 and 8 in TC
Percent changePlaceboBempedoic Acid
Week 42.08 ± 1.000-18.33 ± 1.129
Week 81.82 ± 1.110-16.63 ± 1.215
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -20.41 · 95% CI -23.390 to -17.430
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -18.46 · 95% CI -21.710 to -15.206
Other pre-specifiedPercent Change From Baseline to Weeks 4 and 8 in TGs

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for TGs. Baseline was defined as the mean of the TGs values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(TGs value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TGs was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

Time frame:
Week 4 and Week 8
Reported as:
Least squares mean · Percent change
Percent Change From Baseline to Weeks 4 and 8 in TGs
Percent changePlaceboBempedoic Acid
Week 46.00 ± 4.2735.20 ± 2.536
Week 87.68 ± 4.2467.60 ± 2.849
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = =0.873 · Difference in ls mean: -0.8 · 95% CI -10.663 to 9.059
  • Placebo vs Bempedoic Acid · ANCOVA · p = =0.988 · Difference in ls mean: -0.08 · 95% CI -10.215 to 10.055
Other pre-specifiedPercent Change From Baseline to Weeks 4 and 8 in HDL-C

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for HDL-C. Baseline was defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(HDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.

Time frame:
Week 4 and Week 8
Reported as:
Least squares mean · Percent change
Percent Change From Baseline to Weeks 4 and 8 in HDL-C
Percent changePlaceboBempedoic Acid
Week 40.85 ± 1.204-7.73 ± 1.081
Week 8-1.33 ± 1.272-7.75 ± 1.144
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -8.59 · 95% CI -11.778 to -5.394
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -6.42 · 95% CI -9.798 to -3.049
Other pre-specifiedAbsolute Change From Baseline to Weeks 4, 8, and 12 in LDL-C

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Absolute change from baseline was calculated as: LDL-C value at Week 4, 8, or 12 minus Baseline value.

Time frame:
Week 4, Week 8 and Week 12
Reported as:
Geometric mean · milligrams per deciliter (mg/dL)
Absolute Change From Baseline to Weeks 4, 8, and 12 in LDL-C
milligrams per deciliter (mg/dL)PlaceboBempedoic Acid
Change from Baseline at Week 43.6 ± 15.65-37.4 ± 30.90
Change from Baseline at Week 83.9 ± 19.22-34.5 ± 32.29
Change from Baseline at Week 125.3 ± 23.96-32.9 ± 34.14

Adverse events

Collected over Up to approximately 16 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/87 (0%)3/87 (3.4%)18/87 (20.7%)
Bempedoic Acid0/181 (0%)5/181 (2.8%)46/181 (25.4%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlaceboBempedoic Acid
Pneumonia bacterialInfections and infestations1/870/181
Poisoning deliberateInjury, poisoning and procedural complications1/870/181
Subdural haematomaInjury, poisoning and procedural complications1/870/181
Subdural haemorrhageInjury, poisoning and procedural complications1/870/181
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/870/181
Intestinal obstructionGastrointestinal disorders0/871/181
BronchitisInfections and infestations0/871/181
OsteoarthritisMusculoskeletal and connective tissue disorders0/871/181
Hepatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/871/181
SyncopeNervous system disorders0/871/181
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboBempedoic Acid
Blood uric acid increaseInvestigations2/8714/181
Urinary tract infectionInfections and infestations5/875/181
HeadacheNervous system disorders3/878/181
Liver function test increasedInvestigations0/877/181
Muscle spasmsMusculoskeletal and connective tissue disorders3/876/181
NauseaGastrointestinal disorders0/875/181
SinusitisInfections and infestations0/875/181
VertigoEar and labyrinth disorders2/870/181
Vulvovaginal mycotic infectionInfections and infestations2/870/181
Diabetes mellitusMetabolism and nutrition disorders2/872/181

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboBempedoic AcidTotal
Mean63.7 ± 11.3263.8 ± 10.7763.8 ± 10.93
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBempedoic AcidTotal
Female56109165
Male3272104
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBempedoic AcidTotal
Hispanic or Latino234366
Not Hispanic or Latino65138203
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBempedoic AcidTotal
American Indian or Alaska Native000
Asian134
Native Hawaiian or Other Pacific Islander022
Black or African American101121
White75165240
More than one race202
Unknown or Not Reported000
LDL-C category
LDL-C category(Participants)PlaceboBempedoic AcidTotal
<130 mg/dL5699155
≥130 to <160 mg/dL245377
≥160 mg/dL82937
Concomitant lipid-modifying therapy medications
Concomitant lipid-modifying therapy medications(Participants)PlaceboBempedoic AcidTotal
Statins255984
Fibrates3710
Nicotinic acid and derivatives437
Bile acid sequestrants112
Other lipid-modifying therapies81927
No concomitant lipid-modifying therapies4792139
Concomitant illness: Cardiac disorder
Concomitant illness: Cardiac disorder(Participants)PlaceboBempedoic AcidTotal
Participants with cardiac disorder224971
Participants without cardiac disorder66132198
History of diabetes
History of diabetes(Participants)PlaceboBempedoic AcidTotal
Participants with history of diabetes173552
Participants without history of diabetes71146217

12 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Georgetown, Texas 78626, United States
09

References and documents

Publications

  • Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28;7:13457. doi: 10.1038/ncomms13457. PubMed 27892461 ↗
  • Bilen O, Ballantyne CM. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Curr Atheroscler Rep. 2016 Oct;18(10):61. doi: 10.1007/s11883-016-0611-4. PubMed 27663902 ↗
  • Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, McKenney JM, Ballantyne CM. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016 May-Jun;10(3):556-67. doi: 10.1016/j.jacl.2015.12.025. Epub 2016 Jan 6. PubMed 27206943 ↗
  • Ballantyne CM, McKenney JM, MacDougall DE, Margulies JR, Robinson PL, Hanselman JC, Lalwani ND. Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. Am J Cardiol. 2016 Jun 15;117(12):1928-33. doi: 10.1016/j.amjcard.2016.03.043. Epub 2016 Apr 6. PubMed 27138185 ↗
  • Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, Newton RS. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015 May-Jun;9(3):295-304. doi: 10.1016/j.jacl.2015.03.003. Epub 2015 Mar 19. PubMed 26073387 ↗
  • Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 Oct;277:195-203. doi: 10.1016/j.atherosclerosis.2018.06.002. Epub 2018 Jun 12. PubMed 29910030 ↗
  • Ballantyne CM, Bays HE, Louie MJ, Smart J, Zhang Y, Ray KK. Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid. J Am Heart Assoc. 2022 Aug 2;11(15):e024531. doi: 10.1161/JAHA.121.024531. Epub 2022 Aug 2. PubMed 35916348 ↗
  • Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, Ray KK, Flaim J, Ye Z, Catapano AL. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol. 2020 Oct 1;5(10):1124-1135. doi: 10.1001/jamacardio.2020.2314. PubMed 32609313 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jan 2018, 13 months.

Results were first posted in Apr 2020, 2 years 2 months after primary completion. A results delay was requested in Sep 2018.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2016
First posted
Dec 22, 2016
StartActual
Nov 29, 2016
Primary completionActual
Jan 11, 2018
CompletionActual
Feb 12, 2018
Results delay requested
Sep 21, 2018
Results first posted
Apr 3, 2020
Last update
May 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03001076
Responsible party
Sponsor
First posted
Dec 22, 2016
Start date
Nov 29, 2016
Primary completion
Jan 11, 2018
Completion
Feb 12, 2018
Results posted
Apr 3, 2020
Last update
May 11, 2020

Study contacts

Ron Haberman, MD
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion